The collaboration targets the primary bottlenecks currently hindering spatial biology: inconsistent sample preparation and limited scalability. By integrating Parhelia’s Spatial Station into Sirona Dx’s existing service pipeline, the companies aim to reduce hands-on labor and variability in complex assays, including imaging mass cytometry and cyclic immunofluorescence. This shift is designed to lower costs and enable consistent results across multi-site clinical trials.

Nikolay Samusik, CEO of Parhelia Biosciences, noted that the industry has reached a point where the priority is generating reproducible data at scale rather than just acquiring initial results. Nasry Yassa, CEO of Sirona Dx, added that the partnership provides the necessary infrastructure to bridge the gap between rigorous scientific discovery and the operational requirements of large-scale pharmaceutical development.